Sphingosine kinase 1-interacting protein is a dual regulator of insulin and incretin secretion

FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
Yanyan LiuNobuya Inagaki

Abstract

Our previous study demonstrated that sphingosine kinase 1-interacting protein (SKIP, or Sphkap) is expressed in pancreatic β-cells, and depletion of SKIP enhances glucose-stimulated insulin secretion. We find here that SKIP is also expressed in intestinal K- and L-cells and that secretion of gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) as well as insulin are significantly increased, and blood glucose levels are decreased in SKIP-deficient (SKIP-/-) mice compared with those in wild-type mice. Plasma triglyceride (Tg), LDL cholesterol, and mRNA levels of proinflammatory cytokines in adipose tissues, livers, and intestines were found to be significantly decreased in SKIP-/- mice. The phenotypic characteristics of SKIP-/- mice, including adiposity and attenuation of basal inflammation, were abolished by genetic depletion of GIP. The improvement of glucose tolerance and lipid profiles in SKIP-/- mice were cancelled by GLP-1 receptor antagonist exendin-(9-39) treatment. In summary, depletion of SKIP ameliorates glucose tolerance by enhancing secretion of insulin and incretins, improves lipid metabolism, and reduces basal inflammation levels. Thus, inhibition of SKIP action may emerge as a new option for tr...Continue Reading

References

Apr 29, 1998·The Journal of Clinical Investigation·J SchirraM Katschinski
Jun 10, 2000·Arteriosclerosis, Thrombosis, and Vascular Biology·K HottaY Matsuzawa
Aug 1, 1959·Canadian Journal of Biochemistry and Physiology·E G BLIGH, W J DYER
Nov 19, 2003·Current Opinion in Lipidology·Noriyuki OuchiKenneth Walsh
Oct 27, 2004·Circulation Journal : Official Journal of the Japanese Circulation Society·Miwa RyoTohru Funahashi
Dec 16, 2004·The Journal of Clinical Endocrinology and Metabolism·Mélanie CôtéJean-Pierre Després
Apr 6, 2006·Journal of Biochemistry and Molecular Biology·Tarek Assad TahaLina Marie Obeid
May 25, 2006·Neuroscience Research·Takashi IwaiJun-Ichiro Oka
Jul 11, 2006·The Journal of Clinical Investigation·Takashi KadowakiKazuyuki Tobe
Jul 29, 2006·Diabetes Research and Clinical Practice·K M ChoiS H Baik
Aug 25, 2007·The Journal of Clinical Investigation·Ja-Young KimPhilipp E Scherer
Jan 16, 2009·International Journal of Obesity : Journal of the International Association for the Study of Obesity·T Yamauchi, T Kadowaki
Apr 25, 2009·Obesity·Jeroen NijhuisJan Willem M Greve
Jul 9, 2009·The Journal of Clinical Endocrinology and Metabolism·Murielle BochudValentin Rousson
Apr 16, 2010·Chembiochem : a European Journal of Chemical Biology·Duangnapa KovanichArjen Scholten
Nov 18, 2010·American Journal of Physiology. Endocrinology and Metabolism·A D DobrianJ L Nadler
Aug 9, 2011·Progress in Biophysics and Molecular Biology·Daisuke Yabe, Yutaka Seino
Oct 18, 2011·Trends in Cell Biology·Michael MaceykaSarah Spiegel
Jul 11, 2013·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Yanfei QiPu Xia
Jan 30, 2014·American Journal of Physiology. Endocrinology and Metabolism·Jing WangFahumiya Samad
May 8, 2014·Cardiovascular & Hematological Disorders Drug Targets·Sarah FarrKhosrow Adeli
May 13, 2014·Mediators of Inflammation·Catarina MarquesRosa Fernandes
Oct 31, 2014·World Journal of Gastroenterology : WJG·Xing-Chun WangShen Qu
Dec 30, 2014·American Journal of Physiology. Endocrinology and Metabolism·Shu ChenAkira Shimotoyodome
May 26, 2015·Clinical Lipidology·Jixin ZhongSanjay Rajagopalan

❮ Previous
Next ❯

Citations

Feb 26, 2021·Cellular Signalling·Dominik WiggerBurkhard Kleuser
Jun 22, 2021·Tissue Barriers·Anke C Ziegler, Markus H Gräler

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.